Accessibility of human apolipoprotein B-100 epitopes in insulin-dependent diabetes : Relation with the surface lipid environment of atherogenic particles

Diabetes and Metabolism

Volumn 22, Issue 3, 1996, Pages 179-184

  Ziegler, O ^a   Mejean L ^b   Igau, B ^c   Fruchart, J C ^c   Drouin, P ^a   Fievet C ^c  

^a Ctr Hospitalier Univ de Nancy   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

ApoB 100; Atherosclerosis; Epitopes; Lipids; Type 1 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN B100; EPITOPE; INSULIN;

ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; RISK FACTOR;

ADULT; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; ARTERIOSCLEROSIS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; EPITOPES; HUMANS; LIPOSOMES; MALE; MIDDLE AGED; SURFACE PROPERTIES;

EID: 0030004045     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Kannel WB. Lipids, diabetes and coronary heart disease : insights from the Framingham Study. Am Heart J, 1985, 110, 1100-1107.
2. Taskinen MR. Hormones, diabetes mellitus and lipoproteins. Curr Opin Lipidol, 1991, 2, 197-205.
3. Rivellese A, Riccardi G, Romano G et al. Presence of very low density lipoprotein compositional abnormalities in type I (insulin-dependent) diabetic patients ; effects of blood glucose optimisation. Diabetologia, 1988, 31, 884-888.
4. Bagdade JD, Subbaiah PV. Whole-plasma and high-density lipoprotein subfraction surface lipid composition in IDDM men. Diabetes, 1989, 38, 1226-1230.
5. James RW, Pometta D. Differences in lipoprotein subfraction composition and distribution between type I diabetic men and control subjects. Diabetes, 1990, 39, 1158-1164.
6. Winocour PH, Durrington PN, Bhatnagar D, Ishola M, Arrol S, Mackness M. Abnormalities of VLDL, IDL and LDL characterize insulin-dependent diabetes mellitus. Arterioscler Thromb, 1992, 12, 920-928.
7. Bierman EL. Atherogenesisin diabetes. Arterioscler Thromb, 1992, 12, 647-656.
8. Schonfeld G, Patsch W, Pfleger B, Witztum JL, Weldman SW. Lipolysis produces changes in the immunoreactivity and cell reactivity of very low density lipoprotein. J Clin Invest, 1979, 64, 1288-1297.
9. Witztum JL, Mahoney EM, Branks MJ, Fisher M, Elam R, Steinberg D. Non-enzymatic glycosylation of low density lipoprotein alters its biologic activity. Diabetes, 1982, 31, 283-291.
10. Kleinman Y, Schonfeld G, Gavish D, Oschry Y, Eisenberg S. Hypolipidemic therapy modulates expression of apolipoprotein B epitopes on low density lipoproteins : Studies in mild to moderate hypertriglyceridemic patients. J Lipid Res, 1987, 28, 540-548.
11. Keidar S, Goldberg AC, Cook K, Bateman J, Schonfeld G. High carbohydrate fat-free diet modulates epitope expression of LDL-apo B100 and interaction of LDL with human fibroblasts. J Lipid Res, 1989, 30, 1331-1339.
12. Kleinmann Y, Krul ES, Burnes M, Aronson W, Pfleger B, Schonfeld G. Lipolysis of LDL with phospholipase A2 alters the expression of selected apo B100 epitopes and the interaction of LDL with cells. J Lipid Res, 1988, 29, 729-743.
13. Schonfeld G, Krul ES. Immunologic approaches to lipoprotein structure. J Lipid Res, 1986, 27, 583-601.
14. Krul ES, Kleinman Y, Kinoshita M et al. Regional specificities of monoclonal anti-human apolipoprotein B antibodies. J Lipid Res, 1988, 29, 937-947.
15. Marcel YL, Hogue M, Weech PK, Davignon J, Milne RW. Expression of apolipoprotein B epitopes in lipoproteins : Relationship to conformation and function. Arteriosclerosis, 1988, 8, 832-844.
16. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes, 1979, 28, 1039-1057.
17. Fiévet C, Koffigan M, Ouvry D, Marcovina S, Moschetto Y, Fruchart J-C. Non-competitive enzyme-linked immunoassay for apolipoprotein B in serum. Clin Chem, 1984, 30, 98-100.
18. Luyeye I, Fiévet C, Dupont J-C et al. Human apolipoprotein B : Evidence for its immunochemical heterogeneity using monoclonal antibodies and an immunoenzymometric assay. Clin Biochem, 1988, 21, 255-261.
19. Pease RJ, Milne RW, Jessup WK et al. Use of bacterial expression cloning to localize the epitopes for a series of monoclonal antibodies against apolipoprotein B. J Biol Chem, 1990, 265, 553-568.
20. Fiévet C, Ziegler O, Parra H-J, Méjean L, Fruchart J-C, Drouin P. Depletion in choline containing phospholipids of Lp B particles in adequately controlled type 1 insulin-dependent diabetes mellitus. Diab Metabol, 1990, 16, 64-69.
21. Pascal M, Wülfert E. Evaluation of a new precipitation procedure for estimating high density lipoprotein cholesterol : precipitation of apolipoprotein B-associated cholesterol with concanavalin A. Ann Biol Clin, 1981, 39, 343-350.
22. Egusa G, Brady DW, Grundy SM, Howard BV. Isopropanol precipitation method for the determination of apolipoprotein B specific activity and plasma concentrations during metabolic studies of very low density lipoprotein and low density lipoprotein apolipoprotein B. J Lipid Res. 1983, 24, 1261-1267.
23. Habeeb AFSA. Determination of free amino groups in proteins by trinitrobenzene sulfonic acid. Anal Biochem, 1966, 14, 328-336.
24. Fiévet C, Durieux C, Milne R et al. Rat monoclonal antibodies to human apolipoprotein B : Advantages and applications. J Lipid Res. 1989, 30, 1015-1024.
25. Rodbard D. Statistical quality control and routine data processing for radioimmunoassays and immunoradiometric assays. Clin Chem, 1974, 20, 1255-1270.
26. Taskinen M-R. Hyperlipidemia in diabetes. Bailliere's Clinical Endocrinology and Metabolism, 1990, 4, 743-747.
27. Dunn FL. Hyperlipidemia in diabetes mellitus. Diabetes Metab Rev, 1990, 6, 47-61.
28. Alaupovic P, Lee DM, McConathy WD. Studies on the composition and structure of plasma lipoproteins. Distribution of lipoprotein families in major density classes of normal human plasma lipoproteins. Biochim Biophys Acta, 1972, 260, 689-707.
29. Borensztajn J, Getz GS, Hollar TJ. Uptake of chylomicron remnants by the liver : further evidence for the modulating role of phospholipids. J Lipid Res, 1988, 29, 1087-1096.
30. Chapman MJ, Goldstein S. Human serum low-density lipoprotein : structural studies with phospholipase. Fed Proc, 1976, 35, 379-383.
31. Watt TS, Watt RM. Detection of unique antigenic determinants on human plasma low density lipoprotein and on delipidated apolipoprotein B. Proc Nat Acad Sci USA, 1983, 80, 124-128.
32. Harduin P, Tailleux A, Fruchart J-C, Fiévet C. Modulation of the expression of human LDL-apoB-100 epitopes by lipids and apolipoproteins. Arterioscler Thromb, 1993, 13, 529-535.
33. Fiévet C, Nuttens M-C, Ducimetière P, Fruchart J-C, Bertrand M, Salomez J-L. Relation of arteriographically defined coronary artery disease to serum lipoprotein particles mapped with monoclonal antibodies. Circulation, 1991, 84, 153-159.
34. Milne RW, Blanchette L, Théolis R, Weech PK, Marcel YL. Monoclonal antibodies distinguish between lipid-dependent and reversible conformational states of human apolipoprotein B. Mol Immunol. 1987, 24, 435-447.